Leerink Partnrs Issues Positive Outlook for Beigene Earnings

Beigene, Ltd. (NASDAQ:ONC - Free Report) - Analysts at Leerink Partnrs boosted their Q2 2025 earnings per share (EPS) estimates for shares of Beigene in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.08) for the quarter, up from their prior forecast of ($0.14). The consensus estimate for Beigene's current full-year earnings is ($5.82) per share. Leerink Partnrs also issued estimates for Beigene's Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.16) EPS and FY2027 earnings at $14.07 EPS.

Beigene (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of ($0.71) by $1.93. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%.

Other analysts have also issued research reports about the company. Sanford C. Bernstein set a $259.00 price objective on Beigene in a research report on Thursday, March 13th. JPMorgan Chase & Co. increased their price target on Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, April 21st. Guggenheim lifted their price objective on Beigene from $348.00 to $350.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Macquarie upped their target price on shares of Beigene from $259.00 to $313.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Finally, JMP Securities set a $348.00 price target on shares of Beigene in a research note on Friday, February 28th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $319.00.

Beigene Stock Up 1.4%

Beigene stock traded up $3.24 during mid-day trading on Monday, reaching $229.01. 58,087 shares of the company's stock were exchanged, compared to its average volume of 475,999. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. Beigene has a twelve month low of $141.31 and a twelve month high of $287.88. The firm has a market capitalization of $22.68 billion, a P/E ratio of -27.79, a P/E/G ratio of 7.73 and a beta of 0.35. The stock's fifty day simple moving average is $243.76.

Insider Activity at Beigene

In related news, insider Xiaodong Wang sold 41,760 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $223.50, for a total transaction of $9,333,360.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Xiaobin Wu sold 51,921 shares of Beigene stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total transaction of $14,610,569.40. The disclosure for this sale can be found here. Insiders have sold 1,187,808 shares of company stock valued at $304,531,660 in the last ninety days. Insiders own 6.62% of the company's stock.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.